Zoetis Inc. (NYSE:ZTS) Stake Lessened by Ballentine Partners LLC

Ballentine Partners LLC trimmed its position in Zoetis Inc. (NYSE:ZTS) by 0.9% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 11,933 shares of the company’s stock after selling 107 shares during the period. Ballentine Partners LLC’s holdings in Zoetis were worth $2,019,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in ZTS. Blue Bell Private Wealth Management LLC grew its holdings in Zoetis by 222.5% during the fourth quarter. Blue Bell Private Wealth Management LLC now owns 129 shares of the company’s stock worth $25,000 after acquiring an additional 89 shares during the period. Independence Bank of Kentucky raised its holdings in shares of Zoetis by 371.4% in the 4th quarter. Independence Bank of Kentucky now owns 165 shares of the company’s stock worth $33,000 after purchasing an additional 130 shares in the last quarter. Private Wealth Management Group LLC acquired a new stake in Zoetis during the fourth quarter valued at approximately $33,000. Ramirez Asset Management Inc. bought a new stake in Zoetis during the third quarter worth approximately $35,000. Finally, Gladius Capital Management LP acquired a new position in Zoetis in the fourth quarter worth approximately $40,000. 92.80% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Zoetis news, EVP Roxanne Lagano sold 923 shares of the company’s stock in a transaction dated Thursday, April 18th. The shares were sold at an average price of $151.17, for a total transaction of $139,529.91. Following the completion of the sale, the executive vice president now directly owns 14,800 shares in the company, valued at $2,237,316. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 0.16% of the company’s stock.

Zoetis Stock Down 0.0 %

Shares of NYSE ZTS traded down $0.08 during trading hours on Monday, hitting $171.01. The stock had a trading volume of 59,461 shares, compared to its average volume of 2,947,975. The firm’s 50-day moving average price is $166.56 and its two-hundred day moving average price is $179.18. Zoetis Inc. has a 52 week low of $144.80 and a 52 week high of $201.92. The company has a market capitalization of $78.03 billion, a P/E ratio of 32.84, a P/E/G ratio of 2.61 and a beta of 0.88. The company has a debt-to-equity ratio of 1.30, a quick ratio of 1.94 and a current ratio of 3.33.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Thursday, May 2nd. The company reported $1.38 earnings per share for the quarter, beating analysts’ consensus estimates of $1.34 by $0.04. The business had revenue of $2.19 billion for the quarter, compared to the consensus estimate of $2.14 billion. Zoetis had a net margin of 27.38% and a return on equity of 50.34%. Zoetis’s revenue for the quarter was up 9.5% on a year-over-year basis. During the same quarter last year, the firm earned $1.31 EPS. Analysts anticipate that Zoetis Inc. will post 5.76 EPS for the current fiscal year.

Zoetis Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 4th. Investors of record on Thursday, July 18th will be issued a $0.432 dividend. The ex-dividend date of this dividend is Thursday, July 18th. This represents a $1.73 annualized dividend and a yield of 1.01%. Zoetis’s dividend payout ratio (DPR) is currently 33.33%.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the company. Stifel Nicolaus decreased their target price on Zoetis from $195.00 to $180.00 and set a “buy” rating on the stock in a report on Tuesday, April 30th. HSBC reduced their price objective on shares of Zoetis from $230.00 to $225.00 and set a “buy” rating for the company in a research note on Wednesday, May 8th. Piper Sandler restated an “overweight” rating and set a $195.00 price target (down previously from $220.00) on shares of Zoetis in a report on Tuesday, April 16th. Barclays decreased their price objective on shares of Zoetis from $260.00 to $230.00 and set an “overweight” rating for the company in a research note on Tuesday, April 23rd. Finally, The Goldman Sachs Group reduced their target price on Zoetis from $223.00 to $196.00 and set a “buy” rating for the company in a report on Monday, May 6th. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $211.75.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.